# Near-Infrared Responsive Nanoplatform for Synergistic Photothermal Therapy/Chemotherapy of Lung Cancer

**Authors:** Kangqi Ren, Jian Wang, Lei Xue, Jieyu Liu, Jun Li, Degang Liu, Qiang Yang, Jiangzhou Peng

PMC · DOI: 10.34133/bmr.0319 · Biomaterials Research · 2026-03-06

## TL;DR

A new nanoplatform combines photothermal therapy and chemotherapy to improve lung cancer treatment by enhancing drug retention and reducing resistance.

## Contribution

A novel nanoplatform (TSPD) is developed for synergistic photothermal therapy and chemotherapy using TiO2@SiO2 nanoparticles.

## Key findings

- TSPD rapidly released docetaxel under acidic endosomal conditions, inhibiting tumor cell proliferation.
- NIR irradiation induced hyperthermia, promoting tumor cell death and accelerating drug release.
- TSPD showed prolonged tumor retention in vivo, enhancing therapeutic efficacy.

## Abstract

Lung cancer is one of the most prevalent and lethal solid tumors worldwide. Traditional treatment methods mainly rely on chemotherapeutic drugs, which kill tumor cells by inhibiting their mitosis and proliferation. However, in clinical practice, first-line chemotherapeutic agents often exhibit short half-lives and induce a range of adverse reactions while potentially leading to tumor cell resistance, significantly reducing therapeutic efficacy. To address these issues, we developed a novel nanoplatform (TSPD), which used titanium dioxide (TiO2) as a core template to fabricate porous silica-coated nanoparticles (TiO2@SiO2), further coated with the photothermal agent polydopamine (PDA) and loaded with docetaxel (DTX). Once internalized by tumor cells, TSPD rapidly released DTX under the acidic conditions of the endosomes, effectively inhibiting tumor cell proliferation. Upon near-infrared (NIR) irradiation, TSPD induced localized hyperthermia, which not only promoted tumor cell death but also accelerated the release of DTX. Furthermore, TSPD exhibited a prolonged tumor retention in vivo, markedly increasing drug retention time at the tumor site, thus enhancing the therapeutic effect. This study provides a promising strategy for the development of novel nanomedicines in the synergistic application of photothermal therapy (PTT) and chemotherapy.

## Linked entities

- **Chemicals:** docetaxel (PubChem CID 148124), titanium dioxide (PubChem CID 26042)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Ctr9 (CTR9 homolog, Paf1/RNA polymerase II complex component) [NCBI Gene 22083] {aka Sh2bp1, Tsbp, Tsp, mKIAA0155}, Hspa1b (heat shock protein family A (Hsp70) member 1B) [NCBI Gene 15511] {aka HSP70B1, Hsp70, Hsp70-1, Hsp70.1, hsp68}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Dntt (deoxynucleotidyltransferase, terminal) [NCBI Gene 21673] {aka Tdt}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}
- **Diseases:** cardiac toxicity (MESH:D066126), hyperthermia (MESH:D005334), necrosis (MESH:D009336), neuropathy (MESH:D009422), alopecia (MESH:D000505), breast cancer (MESH:D001943), hypersensitivity (MESH:D004342), Lung Cancer (MESH:D008175), cancer (MESH:D009369), Cytotoxicity (MESH:D064420), stomatitis (MESH:D013280), prostate cancer (MESH:D011471)
- **Chemicals:** eosin (MESH:D004801), dopamine hydrochloride (MESH:D004298), PDA (MESH:C568283), PVDF (MESH:C024865), SDS (MESH:D012967), hydrogen (MESH:D006859), ethanol (MESH:D000431), DTX (MESH:D000077143), 4',6-diamidino-2-phenylindole (MESH:C007293), deoxyuridine (MESH:D003857), water (MESH:D014867), TiO2 (MESH:C009495), CO2 (MESH:D002245), paraformaldehyde (MESH:C003043), ammonium hydroxide (MESH:D064753), PTX (MESH:D017239), EDTA (MESH:D004492), PEG (MESH:D011092), TiO2@SiO2 (MESH:C507641), streptomycin (MESH:D013307), Alexa Fluor 488 (MESH:C000711379), ICG (MESH:D007208), Annexin V-FITC (-), PI (MESH:D011419), calcein-AM (MESH:C085925), paraffin (MESH:D010232), saline (MESH:D012965), JC-1 (MESH:C068624), silica (MESH:D012822), penicillin (MESH:D010406), hematoxylin (MESH:D006416)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), AC16 — Homo sapiens (Human), Transformed cell line (CVCL_HA69), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), A549 lung tumor — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_VU37)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963644/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963644/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963644/full.md

---
Source: https://tomesphere.com/paper/PMC12963644